Results 101 to 110 of about 4,142 (167)

Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region. [PDF]

Clin Pract
Gemma GPA, Bernardini N, Sasso FP, Caldarola G, De Luca E, Greco ME, Lora V, Mazzotta A, Miraglia E, Orsini D, Pagnanelli G, Richetta AG, Skroza N, Dattola A.   +13 more
europepmc   +1 more source

A new association of cutaneous leishmaniasis with guselkumab in a patient with chronic psoriasis. [PDF]

Skin Health Dis
Chiang YH, Winter S, Kalavala M.
europepmc   +1 more source

Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases. [PDF]

Clin Pharmacokinet
Pool IA, de Groot ADE, Keizer RJ, Dubinsky MC, Torres J, Atreya R, Malik P, Dreesen E, Dijkstra G, Verkade HJ, Mian P, Bourgonje AR.   +11 more
europepmc   +1 more source

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, Burzi L, Castelli F, Chiarpenello M, Graziola F, Leporati C, Ortoncelli M, Pella P, Pertusi G, Pisterna A, Quaglino P, Ribero S, Rossotto G, Tiberio R, Dapavo P, Savoia P.   +20 more
europepmc   +1 more source

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Zhang S, Lam T, Du Y, Chen X, Zhang H, Li L, Zhang G.   +6 more
europepmc   +1 more source

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Richard N, Fumery M.
europepmc   +1 more source

Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report. [PDF]

Cureus
Furuichi N, Itoi Y, Oshima K, Takeuchi Y, Uraoka T.   +4 more
europepmc   +1 more source

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Hsu CC, Huang YH, Tsai TF.
europepmc   +1 more source

New Drug: Guselkumab for plaque psoriasis [PDF]

Australian Prescriber, 2019
openaire   +2 more sources

Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab. [PDF]

JAAD Case Rep
Craver AE, McKenzie P, Hanly A, Vesely MD.   +3 more
europepmc   +1 more source